Bernard BSc - Cardiol Therapeutics Chief Officer
| CRDL Stock | CAD 2.18 0.08 3.54% |
Insider
Bernard BSc is Chief Officer of Cardiol Therapeutics Class
| Address | 2265 Upper Middle Road East, Oakville, ON, Canada, L6H 0G5 |
| Phone | 289-910-0850 |
| Web | https://www.cardiolrx.com |
Cardiol Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.5415) % which means that it has lost $0.5415 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.0844) %, meaning that it generated substantial loss on money invested by shareholders. Cardiol Therapeutics' management efficiency ratios could be used to measure how well Cardiol Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 26th of November 2024, Return On Tangible Assets is likely to drop to -0.81. In addition to that, Return On Capital Employed is likely to drop to -1.1. At this time, Cardiol Therapeutics' Total Assets are very stable compared to the past year. As of the 26th of November 2024, Non Current Assets Total is likely to grow to about 610.6 K, while Net Tangible Assets are likely to drop about 32.7 M.Similar Executives
| Found 9 records | INSIDER Age | ||
| James Shelford | Altagas Cum Red | 39 | |
| Esq BComm | Altagas Cum Red | N/A | |
| Joy Thakur | Altagas Cum Red | N/A | |
| Corine Bushfield | Altagas Cum Red | 48 | |
| Kent Stout | Altagas Cum Red | N/A | |
| Phillip Burns | European Residential Real | 55 | |
| Jenny Chou | European Residential Real | N/A | |
| Randall Crawford | Altagas Cum Red | 60 | |
| Jon Morrison | Altagas Cum Red | N/A | |
Management Performance
| Return On Equity | -1.08 | ||||
| Return On Asset | -0.54 |
Cardiol Therapeutics Leadership Team
Elected by the shareholders, the Cardiol Therapeutics' board of directors comprises two types of representatives: Cardiol Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cardiol. The board's role is to monitor Cardiol Therapeutics' management team and ensure that shareholders' interests are well served. Cardiol Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cardiol Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Andrew MD, Chief Development | ||
| Trevor Burns, Investor Relations | ||
| Bernard BSc, Chief Officer | ||
| MBA BSCPT, Vice Development | ||
| MBA MBA, CEO Pres | ||
| David MBA, CEO President | ||
| CA CMA, Corp CFO |
Cardiol Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cardiol Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.08 | ||||
| Return On Asset | -0.54 | ||||
| Current Valuation | 168.7 M | ||||
| Shares Outstanding | 81.6 M | ||||
| Shares Owned By Insiders | 3.91 % | ||||
| Shares Owned By Institutions | 9.50 % | ||||
| Number Of Shares Shorted | 263.21 K | ||||
| Price To Book | 17.68 X | ||||
| Price To Sales | 1,274 X | ||||
| Gross Profit | 78.76 K |
Pair Trading with Cardiol Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cardiol Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cardiol Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Cardiol Stock
The ability to find closely correlated positions to Cardiol Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cardiol Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cardiol Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cardiol Therapeutics Class to buy it.
The correlation of Cardiol Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cardiol Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cardiol Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cardiol Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiol Therapeutics Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.